유럽 연합 - 독일어 - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sonidegib-diphosphat - karzinom, basalzelle - antineoplastische mittel - odomzo ist zur behandlung von erwachsenen patienten mit lokal fortgeschrittenem basalzellkarzinom (bcc) indiziert, die keiner kurativen operation oder strahlentherapie zugänglich sind.

유럽 연합 - 독일어 - EMA (European Medicines Agency)

medac gesellschaft fuer klinische spezialpraeparate mbh - asparaginase - vorläuferzelle lymphoblastische leukämie-lymphom - antineoplastische mittel - spectrila ist indiziert als ein bestandteil der antineoplastischen kombinationstherapie zur behandlung von akuter lymphoblastischer leukämie (all) bei pädiatrischen patienten von der geburt bis zum 18. lebensjahr und bei erwachsenen.

스위스 - 독일어 - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - vismodegibum - kapseln - vismodegibum 150 mg, cellulosum microcristallinum, lactosum monohydricum 71.5 mg, natrii laurilsulfas, povidonum k 29-32, carboxymethylamylum natricum, talcum, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (rubrum), e 172 (nigrum), drucktinte: lacca, e 172 (nigrum), excipiens pro capsula corresp. natrium 1.09 - 1.34 mg. - zytostatikum - synthetika

스위스 - 독일어 - Swissmedic (Swiss Agency for Therapeutic Products)

sun pharma switzerland ltd - sonidegibum - hartkapseln - sonidegibum 200 mg ut sonidegibi diphosphas, crospovidonum, lactosum monohydricum 38.60 mg, poloxamerum 188, natrii laurilsulfas corresp. natrium 0.605 mg, magnesii stearas, silica colloidalis anhydrica, kapselhülle: gelatina, e 171, e 172 (rubrum), drucktinte: lacca, e 172 (nigrum), propylenglycolum q.s., pro capsula. - basalzellkarzinom - synthetika

스위스 - 독일어 - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - olaparibum - kapseln - olaparibum 50 mg, macrogolglyceridorum laurates, kapselhülle: hypromellosum, e 171, gellani gummi, kalii acetas, drucktinte: lacca, e 172 (nigrum), pro capsula. - onkologikum - synthetika

유럽 연합 - 독일어 - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - niraparib (tosilate monohydrate) - fallopian tube neoplasms; peritoneal neoplasms; ovarian neoplasms - antineoplastische mittel - zejula is indicated: , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (figo stages iii and iv) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. , as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.

스위스 - 독일어 - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - olaparibum - filmtabletten - olaparibum 100 mg, copovidonum k 28, silica colloidalis anhydrica, mannitolum, natrii stearylis fumaras corresp. natrium 0.236 mg, Überzug: hypromellosum, macrogolum 400, e 171, e 172 (flavum), pro compresso obducto. - onkologikum - synthetika

스위스 - 독일어 - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - olaparibum - filmtabletten - olaparibum 150 mg, copovidonum k 28, silica colloidalis anhydrica, mannitolum, natrii stearylis fumaras corresp. natrium 0.354 mg, Überzug: hypromellosum, macrogolum 400, e 171, e 172 (flavum), e 172 (nigrum), pro compresso obducto. - onkologikum - synthetika

유럽 연합 - 독일어 - EMA (European Medicines Agency)

pharmaand gmbh - rucaparib camsylate - eierstock-neoplasmen - antineoplastische mittel - rubraca is indicated as monotherapy for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. rubraca ist indiziert als monotherapie für die erhaltungstherapie von erwachsenen patientinnen mit platin-sensiblen rezidiv einer hochgradigen epithelialen eierstockkrebs, eileiterkrebs oder primärem peritonealkarzinom, die in reaktion (vollständige oder teilweise) auf platin-basierte chemotherapie.

유럽 연합 - 독일어 - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - andere antineoplastische mittel - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.